CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP MOUTHWASH

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CHLORHEXIDINE GLUCONATE

Prieinama:

SAGE PRODUCTS LLC

ATC kodas:

A01AB03

INN (Tarptautinis Pavadinimas):

CHLORHEXIDINE

Dozė:

0.12%

Vaisto forma:

MOUTHWASH

Sudėtis:

CHLORHEXIDINE GLUCONATE 0.12%

Vartojimo būdas:

BUCCAL

Vienetai pakuotėje:

15ML/473ML

Recepto tipas:

Prescription

Gydymo sritis:

MISCELLANEOUS ANTI-INFECTIVES

Produkto santrauka:

Active ingredient group (AIG) number: 0107629007; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2022-04-22

Prekės savybės

_ _
_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP
Chlorhexidine Gluconate 0.12% Oral Rinse
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Sage Product LLC
3909 Three Oaks Road
Cary, IL 60013
USA
Date of Preparation:
February 17, 2015
Submission Control No: 180308
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................6
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEUTICAL INFORMATION
..........................................................................11
CLINICAL TRIALS
..........................................................................................................12
DETAILED PHARMACOLOGY
.........................